Human T-lymphotropic virus 2 | |
---|---|
Specialty | Infectious diseases |
Symptoms | Mild cognitive Impairment, Mycosis fungoides |
Duration | Chronic, incurable |
Causes | HTLV-2 |
Risk factors | Unsafe sex, haemophiliacs |
Diagnostic method | Blood test |
Differential diagnosis | HIV/AIDS, Lymphoma, HTLV-1 |
Prevention | Practicing safe-sex, use of clean needles, screening blood transfusions, Avoiding breastfeeding. |
Medication | Antiretrovirals, chemotherapy |
Prognosis | 95% present with no symptoms, generally good |
Frequency | 15-20 million people worldwide |
Primate T-lymphotropic virus 2 | |
---|---|
Virus classification | |
(unranked): | Virus |
Realm: | Riboviria |
Kingdom: | Pararnavirae |
Phylum: | Artverviricota |
Class: | Revtraviricetes |
Order: | Ortervirales |
Family: | Retroviridae |
Genus: | Deltaretrovirus |
Species: | Primate T-lymphotropic virus 2
|
A virus closely related to HTLV-I, human T-lymphotropic virus 2 (HTLV-II) shares approximately 70% genomic homology (structural similarity) with HTLV-I. It was discovered by Robert Gallo and colleagues.[1][2]
HTLV-2 is prevalent among the indigenous populations in Africa and the Indian-American tribes in Central and South America as well as among drug users in Europe and North America[3] It can be passed down from mother to child through breastmilk and genetically as well from either parent.
HTLV-II entry in target cells is mediated by the glucose transporter GLUT1.[4]